A research team identified three genes – CYP2C19, SLCO1B1, and CYP2C9 – as priorities for pharmacogenomic testing in older Chinese adults receiving multiple medications. The analysis of over 3.3 million patient records revealed that approximately one in five patients received exposure to at least two drugs with established genetic prescribing guidance. The study examined data from 2015 through 2017, focusing on adults aged 65 years or older, and standardized medication names to active ingredients for comparison with Clinical Pharmacogenetics Implementation Consortium Level A drug–gene guidance. The research defined primary exposure as receiving at least two distinct relevant drugs within one calendar year.
Coverage of these genes was extensive, with CYP2C19 and SLCO1B1 together covering approximately 96% of records meeting the two-drug threshold, and adding CYP2C9 increased coverage to at least 98%. The study considered a fee schedule from Zhejiang Province, comparing the cost of a combined panel of 11 loci at CNY 2,200 to CNY 2,800 for three separately billed gene tests.
Atorvastatin and pantoprazole were identified as the most frequent medications associated with the two-drug threshold, and statins and proton pump inhibitors were prominent therapeutic classes. The findings provide a basis for evaluating targeted genetic testing to support personalized medication management, acknowledging that the data represents unweighted insurance samples and annual exposure does not necessarily reflect simultaneous medication use. Further prospective research is needed to determine the impact of these genes on treatment decisions, patient safety, and value in clinical care.